Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. - Wikidata - wikimedia - TriplyDB

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

http://www.wikidata.org/entity/Q34853030

about

Emerging approaches in Parkinson's disease - adjunctive role of safinamide Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide Pharmacology and Clinical Drug Candidates in Redox Medicine New treatments for the motor symptoms of Parkinson's disease.The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Recent advances in treating Parkinson's disease.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease.Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.Emerging drugs for levodopa-induced dyskinesia.Safinamide for the treatment of Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Safinamide: first global approval.Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Rational drug discovery design approaches for treating Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.New treatments for levodopa-induced motor complications.Modern treatment in Parkinson's disease, a personal approach.Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.New and emerging medical therapies in Parkinson's disease.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Safinamide: A Review in Parkinson's Disease.Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?Formulary Drug Review: Safinamide.Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.[Pharmacological treatment of motor symptoms in Parkinson's diseases].Safinamide: an add-on treatment for managing Parkinson's disease.Motor Complications of Dopaminergic Medications in Parkinson's Disease.Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence

P2860

Q26740905-5BC86EAF-CC6D-426A-9C60-F93794F15548 Q26766289-A6A5EACE-5152-403A-B14F-1D53F46C8886 Q26785525-1EDD27DA-32A9-4D02-8362-2BC47412194B Q34443682-BB672A20-8EA5-44ED-B476-5BA3A385A6CB Q34512544-3E1A646D-FBBF-468D-9F25-0A4987B0715D Q34554401-B8BC11BB-48D1-4EBF-BA2B-31025811115E Q36925905-6FB9F5F4-874E-4444-BEDF-487668576798 Q37054010-02AF50E1-3F8E-4049-9F05-81B1F9F1A124 Q37303004-F3380C81-9E72-41EC-ABB8-2F04E3DF8219 Q37635600-6E0F5904-9D64-4E06-8029-9918747A05BB Q38242091-45DF1184-0525-4752-934F-6E470443C810 Q38258514-794F6537-A9D2-4FA2-A555-7B4F4735FD17 Q38262418-BA731A3F-07CF-4CA7-9609-1E5454E7462A Q38410199-17BA1ABF-2856-433C-83D0-9B2076DE56F9 Q38476557-D1BB41E7-9603-4285-8949-E0D66A116712 Q38478999-15381C25-C794-44CC-865B-694257FEEE1A Q38520864-975F2443-61AB-432E-A021-D59DD5464CDA Q38545359-2ECC96D0-C408-4C3E-99ED-9E25B685BCA6 Q38570434-354E28E2-CDF1-4CB8-8315-6CF8B78FA0F4 Q38570529-BAFF4510-8FDA-4D3A-B6B8-B0C7FB916522 Q38640108-3F29446F-5BFD-4BE3-8B05-DD5A1B6C2BB1 Q38640744-3F3C2DD1-1878-40A1-9E4E-C30FE4F41AFA Q38718194-FFE3323F-2806-43DC-A918-EB16A6ABC44C Q38817972-0F6569D7-7E9F-4E09-B1A8-73094C166E8B Q38845546-CA61FB49-A4BB-412A-9038-0B2A8D28EA8B Q39097789-0B2920B7-5472-4CF0-965A-86B3C3E171B4 Q39325939-07EC39B8-A8CA-4E9C-ABEE-D05D48608732 Q39350609-0338575F-978A-44B1-887E-31EA225134D7 Q42531922-2B7B10EC-C992-4F74-B80B-C93DD01FD960 Q47319471-5A93CA23-D093-4458-B98C-6121B1AADBA1 Q47962428-DB26E6D8-E657-440A-9EFE-46A2D2DBDD5B Q48108548-ACE82D3A-83C5-48A4-8C3A-6984F51A02A8 Q48250410-806B9AFE-AAB7-4F77-B974-C0E56C4142AE Q48345426-AEBF5A1B-A939-4528-8B7A-D206A75FA7FC Q49587005-67B9E119-9B00-483C-900B-EC4B71A68A67 Q51739969-158B99FD-7228-4C2E-84BF-717D830FD255 Q52703430-3A497F43-1A00-416F-911F-F4021F2FF304 Q52804779-B714458C-C76B-453C-8DC4-0B2C7747703A Q55279095-3A43A8EA-5BD3-4270-A63A-A15D2A06DD75 Q57074141-B605B0EA-C48C-46CF-8C4F-88BBB81E4F46

P2860

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

http://www.wikidata.org/entity/Q34853030

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Randomized trial of safinamide ...... sease with motor fluctuations.

@ast

Randomized trial of safinamide ...... sease with motor fluctuations.

@en

Randomized trial of safinamide ...... sease with motor fluctuations.

@nl

type

label

Randomized trial of safinamide ...... sease with motor fluctuations.

@ast

Randomized trial of safinamide ...... sease with motor fluctuations.

@en

Randomized trial of safinamide ...... sease with motor fluctuations.

@nl

prefLabel

Randomized trial of safinamide ...... sease with motor fluctuations.

@ast

Randomized trial of safinamide ...... sease with motor fluctuations.

@en

Randomized trial of safinamide ...... sease with motor fluctuations.

@nl

P1433

Q34853030-50A13F01-C276-4A4E-BAC6-18D245AE19C0

P1476

Q34853030-9A826284-5EA9-43C1-B2BD-04CECF15DDA7

P2093

Q34853030-0CA0852D-7DBB-4BA6-BC37-E2749F2E0665

Q34853030-1E897117-AAF5-4D21-AF58-209585C957D9

Q34853030-48F9F9F9-BE66-4B63-9C0E-FA664A81CFD9

Q34853030-5C882D4B-A41D-4C17-BBB8-2E1F81B02BA1

Q34853030-A4218EE3-E898-4CE0-9CB9-B35F884B00AC

Q34853030-AA1BDDF7-B4E4-4C3D-B5EC-16DC51C0D6D7

Q34853030-ABAF182A-7798-409D-A167-91C8C07DE6F9

Q34853030-B6154FA6-5488-4E00-832F-655340A572BA

Q34853030-B9EFC1D8-E798-4126-807C-27F091E6F61A

Q34853030-CAFD1D41-B9A6-4BDF-AC5C-9C3AEF68EA24

P2860

Q34853030-275E370C-8CFC-4271-97B4-D6D1DA89BC82

Q34853030-2D0F2A6E-E9E0-46DF-9E54-CEB388BD5523

Q34853030-2EE08AD2-6019-4D23-82F9-66801F4B6E48

Q34853030-334ACDB5-DDBA-4EC4-8279-B1BE5D425D47

Q34853030-473879D6-DED5-4D89-A26E-F9A5EB156B41

Q34853030-4EC1E2A6-E088-4194-9997-50C4DDC94ADE

Q34853030-56C1FAF9-C91D-4AEA-BE44-71720B5F3546

Q34853030-5A622BF1-EE96-4684-BD98-AEF93B38D779

Q34853030-6E488604-0746-4644-A97E-58452FB124D0

Q34853030-73C3D41F-FADA-4A1E-AB67-B50999952785

P304

Q34853030-48B73F7E-4481-45AD-8085-6B59A1E0241B

P31

Q34853030-9046D09D-C0B6-4CE2-A744-A11EB5629C02

P356

Q34853030-F03ABC8D-6E53-466F-9F73-31C6EC321F4F

P407

Q34853030-F000F460-71EA-490E-B8C7-55DFBEA253FA

P433

Q34853030-8D01C3E5-1CC8-495D-9CD3-02BAC6A4BAB0

P478

Q34853030-EE7D7936-3B22-4283-8324-934BAE886EDC

P50

Q34853030-03C68B56-3C14-43CA-AF2D-3989B333C754

Q34853030-F4E922EB-E6D5-4F97-B362-8C6142E7A6AC

P577

Q34853030-FFB7B681-525F-456F-BDE7-73F72ED42813

P5875

Q34853030-1F2689BC-37A6-4739-8821-58BD20F58CC0

P698

Q34853030-3CF72E59-2BAE-409C-ACED-B6C1EE486B9E

P921

Q34853030-BC898DEA-996E-41B0-B5CD-C643303D8225

Q34853030-F73CDAAB-6EE7-4C02-A0BA-1F6F2305A4A7

P932

Q34853030-CF8CDE97-82C7-43CF-8582-C1DFE3163920

P356

P1433

Movement Disorders

P1476

Randomized trial of safinamide ...... sease with motor fluctuations.

@en

P2093

C Meshram

http://www.w3.org/2001/XMLSchema#string

D Chirilineau

http://www.w3.org/2001/XMLSchema#string

E Forrest

http://www.w3.org/2001/XMLSchema#string

M Bhatt

http://www.w3.org/2001/XMLSchema#string

P Rice

http://www.w3.org/2001/XMLSchema#string

P Stanzione

http://www.w3.org/2001/XMLSchema#string

R Anand

http://www.w3.org/2001/XMLSchema#string

R Giuliani

http://www.w3.org/2001/XMLSchema#string

Rupam Borgohain

http://www.w3.org/2001/XMLSchema#string

Study 016 Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives.

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

Safinamide: from molecular targets to a new anti-Parkinson drug.

Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.

The FDA guidance for industry on PROs: the point of view of a pharmaceutical company

Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

Levodopa therapeutics for Parkinson's disease: new developments.

Levodopa: past, present, and future.

P304

229-237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25751

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Fabrizio Stocchi

P577

2013-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262045532

http://www.w3.org/2001/XMLSchema#string

P698

24323641

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4285943

http://www.w3.org/2001/XMLSchema#string